Q3756231 (Q3756231): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Created claim: summary (P836): Pharmaceutical and biotechnology have been identified as one of the three smart specialisation priorities in Southwest Finland. Its aim is to create the conditions for new innovations and their commercialisation through seamless cooperation between research institutes and companies in the field. The needs identified in the preparation of the Bio- and Pharmaceutical Industry (AMBioPharma) are the key to increasing the potential of these sectors....) |
||||||||||||||
| Property / summary | |||||||||||||||
Pharmaceutical and biotechnology have been identified as one of the three smart specialisation priorities in Southwest Finland. Its aim is to create the conditions for new innovations and their commercialisation through seamless cooperation between research institutes and companies in the field. The needs identified in the preparation of the Bio- and Pharmaceutical Industry (AMBioPharma) are the key to increasing the potential of these sectors. The project is based on the near-term development needs of the companies in the field and offers opportunities for new innovations and business activities by developing more manufacturing, i.e. 3D printing. The importance of 3D printing is rapidly increasing in the development of bio- and medical applications. Companies operating in the sector need to develop knowledge, materials and equipment. In summary, the conscious needs of enterprises in the V-S region relate to the efficiency and facilitation of production and the development of new products. Main objectives:1. The project will improve and accelerate companies’ product development through 3D printing of new pharmaceuticals, dentures, medical instruments and in vitro diagnostic test systems. 2. The importance of increasing manufacturing/3D-printing as part of the development of new products will increase in the bio- and pharmaceutical industry in Southwest Finland and increase companies’ innovation capacity and near-term turnover. 3. The use of increasing production/3D printing in companies’ RDI operations and production equipment is increasing. 4. The use of materials is diversified and leads to the development of new products. 5. Cooperation between companies that develop and manufacture 3D printing equipment and components, as well as different sectors of the bio- and pharmaceutical sector, will increase and the level of competence in 3D printing will increase. The project will be implemented in cooperation between the participating organisations through five sets of measures: 1. Development of medicinal products 2. Manufacture of dental loose prostheses with 3D printing and optimisation and design of reinforcement and manufacturing 3. Development of in vitro diagnostic test cassettes and test cassettes with 3D printing 4. Forecasting of the regulatory situation in relation to 3D printing in the bio- and pharmaceutical industries 5. Feedback and design events with companies. The versatile 3D printing testing carried out in the project with different devices and materials produces information that target companies use in product development and design. These include, for example, practical knowledge of 3D printability and manufacturing processes of various materials used in bio- and pharmaceutical applications. The development work carried out in cooperation with companies supports the assessment of future changes in regulation and quality assurance and directs the development work in the right direction. Versatile material testing and practical experience lead to the development of 3D printing equipment and 3D printing processes design and automation. The development of 3D printing in a multidisciplinary manner enables increased cooperation between the different sectors of the bio- and pharmaceutical sector and between companies manufacturing 3D equipment. The results contribute to the growth of RDI activities related to 3D printing and, in the longer term, to the development of new healthcare products and services, the growth of turnover and job creation.The project contributes in many ways to the horizontal objectives of the Structural Funds programme. The use of automation and digitalisation, as well as improved planning in the development of manufacturing, have a positive impact on both ecological and economic sustainability, reducing the use of natural resources, waste of materials and the use of chemicals that are harmful to nature. The project thus increases environmental know-how and contributes to reducing the risks posed by climate change. The bio- and pharmaceutical industry is one of the top priorities of the provincial regional strategy and recovery plans, and the project directly supports the development of the local economic fabric and competitiveness, thereby contributing to the well-being of society. The project also takes into account equality and entrepreneurs from different cultural backgrounds in order to benefit from the project as diverse as possible. (English) | |||||||||||||||
| Property / summary: Pharmaceutical and biotechnology have been identified as one of the three smart specialisation priorities in Southwest Finland. Its aim is to create the conditions for new innovations and their commercialisation through seamless cooperation between research institutes and companies in the field. The needs identified in the preparation of the Bio- and Pharmaceutical Industry (AMBioPharma) are the key to increasing the potential of these sectors. The project is based on the near-term development needs of the companies in the field and offers opportunities for new innovations and business activities by developing more manufacturing, i.e. 3D printing. The importance of 3D printing is rapidly increasing in the development of bio- and medical applications. Companies operating in the sector need to develop knowledge, materials and equipment. In summary, the conscious needs of enterprises in the V-S region relate to the efficiency and facilitation of production and the development of new products. Main objectives:1. The project will improve and accelerate companies’ product development through 3D printing of new pharmaceuticals, dentures, medical instruments and in vitro diagnostic test systems. 2. The importance of increasing manufacturing/3D-printing as part of the development of new products will increase in the bio- and pharmaceutical industry in Southwest Finland and increase companies’ innovation capacity and near-term turnover. 3. The use of increasing production/3D printing in companies’ RDI operations and production equipment is increasing. 4. The use of materials is diversified and leads to the development of new products. 5. Cooperation between companies that develop and manufacture 3D printing equipment and components, as well as different sectors of the bio- and pharmaceutical sector, will increase and the level of competence in 3D printing will increase. The project will be implemented in cooperation between the participating organisations through five sets of measures: 1. Development of medicinal products 2. Manufacture of dental loose prostheses with 3D printing and optimisation and design of reinforcement and manufacturing 3. Development of in vitro diagnostic test cassettes and test cassettes with 3D printing 4. Forecasting of the regulatory situation in relation to 3D printing in the bio- and pharmaceutical industries 5. Feedback and design events with companies. The versatile 3D printing testing carried out in the project with different devices and materials produces information that target companies use in product development and design. These include, for example, practical knowledge of 3D printability and manufacturing processes of various materials used in bio- and pharmaceutical applications. The development work carried out in cooperation with companies supports the assessment of future changes in regulation and quality assurance and directs the development work in the right direction. Versatile material testing and practical experience lead to the development of 3D printing equipment and 3D printing processes design and automation. The development of 3D printing in a multidisciplinary manner enables increased cooperation between the different sectors of the bio- and pharmaceutical sector and between companies manufacturing 3D equipment. The results contribute to the growth of RDI activities related to 3D printing and, in the longer term, to the development of new healthcare products and services, the growth of turnover and job creation.The project contributes in many ways to the horizontal objectives of the Structural Funds programme. The use of automation and digitalisation, as well as improved planning in the development of manufacturing, have a positive impact on both ecological and economic sustainability, reducing the use of natural resources, waste of materials and the use of chemicals that are harmful to nature. The project thus increases environmental know-how and contributes to reducing the risks posed by climate change. The bio- and pharmaceutical industry is one of the top priorities of the provincial regional strategy and recovery plans, and the project directly supports the development of the local economic fabric and competitiveness, thereby contributing to the well-being of society. The project also takes into account equality and entrepreneurs from different cultural backgrounds in order to benefit from the project as diverse as possible. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Pharmaceutical and biotechnology have been identified as one of the three smart specialisation priorities in Southwest Finland. Its aim is to create the conditions for new innovations and their commercialisation through seamless cooperation between research institutes and companies in the field. The needs identified in the preparation of the Bio- and Pharmaceutical Industry (AMBioPharma) are the key to increasing the potential of these sectors. The project is based on the near-term development needs of the companies in the field and offers opportunities for new innovations and business activities by developing more manufacturing, i.e. 3D printing. The importance of 3D printing is rapidly increasing in the development of bio- and medical applications. Companies operating in the sector need to develop knowledge, materials and equipment. In summary, the conscious needs of enterprises in the V-S region relate to the efficiency and facilitation of production and the development of new products. Main objectives:1. The project will improve and accelerate companies’ product development through 3D printing of new pharmaceuticals, dentures, medical instruments and in vitro diagnostic test systems. 2. The importance of increasing manufacturing/3D-printing as part of the development of new products will increase in the bio- and pharmaceutical industry in Southwest Finland and increase companies’ innovation capacity and near-term turnover. 3. The use of increasing production/3D printing in companies’ RDI operations and production equipment is increasing. 4. The use of materials is diversified and leads to the development of new products. 5. Cooperation between companies that develop and manufacture 3D printing equipment and components, as well as different sectors of the bio- and pharmaceutical sector, will increase and the level of competence in 3D printing will increase. The project will be implemented in cooperation between the participating organisations through five sets of measures: 1. Development of medicinal products 2. Manufacture of dental loose prostheses with 3D printing and optimisation and design of reinforcement and manufacturing 3. Development of in vitro diagnostic test cassettes and test cassettes with 3D printing 4. Forecasting of the regulatory situation in relation to 3D printing in the bio- and pharmaceutical industries 5. Feedback and design events with companies. The versatile 3D printing testing carried out in the project with different devices and materials produces information that target companies use in product development and design. These include, for example, practical knowledge of 3D printability and manufacturing processes of various materials used in bio- and pharmaceutical applications. The development work carried out in cooperation with companies supports the assessment of future changes in regulation and quality assurance and directs the development work in the right direction. Versatile material testing and practical experience lead to the development of 3D printing equipment and 3D printing processes design and automation. The development of 3D printing in a multidisciplinary manner enables increased cooperation between the different sectors of the bio- and pharmaceutical sector and between companies manufacturing 3D equipment. The results contribute to the growth of RDI activities related to 3D printing and, in the longer term, to the development of new healthcare products and services, the growth of turnover and job creation.The project contributes in many ways to the horizontal objectives of the Structural Funds programme. The use of automation and digitalisation, as well as improved planning in the development of manufacturing, have a positive impact on both ecological and economic sustainability, reducing the use of natural resources, waste of materials and the use of chemicals that are harmful to nature. The project thus increases environmental know-how and contributes to reducing the risks posed by climate change. The bio- and pharmaceutical industry is one of the top priorities of the provincial regional strategy and recovery plans, and the project directly supports the development of the local economic fabric and competitiveness, thereby contributing to the well-being of society. The project also takes into account equality and entrepreneurs from different cultural backgrounds in order to benefit from the project as diverse as possible. (English) / qualifier | |||||||||||||||
point in time: 23 November 2021
| |||||||||||||||
Revision as of 03:49, 23 November 2021
Project Q3756231 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3756231 in France |
Statements
603,774 Euro
0 references
754,718.0 Euro
0 references
80.0 percent
0 references
1 September 2021
0 references
31 August 2023
0 references
Turun ammattikorkeakoulu Oy
0 references
Lääke- ja bioteknologia on määritetty yhdeksi Varsinais-Suomen kolmesta älykkään erikoistumisen painopisteistä. Sen tavoitteena on alan tutkimusinstituuttien ja yritysten saumattomalla yhteistyöllä luoda edellytyksiä uusille innovaatioille ja niiden kaupallistamiselle. Lisäävän valmistuksen keskus bio- ja lääketeollisuudelle (AMBioPharma) valmistelussa tunnistetut tarpeet vastaavat juuri näiden sektoreiden potentiaalin kasvattamiseen. Hanke pohjautuu alan yritysten lähiajan kehitystarpeisiin ja tarjoaa mahdollisuuksia uusiin innovaatioihin ja liiketoimintaan kehittämällä lisäävää valmistusta eli 3D-tulostusta. 3D-tulostuksen merkitys on nopeasti nousemassa bio- ja lääketieteen sovellusten kehittämisessä. Alalla toimivilla yrityksillä on tarvetta sekä osaamisen, materiaalien että laitteistojen kehittämiseen. Kokoavasti voidaan todeta, että V-S alueen yritysten tiedostetut tarpeet liittyvät tuotannon tehostamiseen ja helpottamiseen sekä uusien tuotteiden kehittämiseen. Päätavoitteet:1. Hanke parantaa ja nopeuttaa yritysten tuotekehitystä uusien lääkevalmisteiden, hammasproteesien, lääkinnällisten instrumenttien ja in vitro-diagnostiikan testijärjestelmien osalta 3D-tulostuksen avulla. 2. Lisäävän valmistuksen/3D-tulostuksen merkitys osana uusien tuotteiden kehitystä kasvaa Varsinais-Suomen bio- ja lääketeollisuudessa ja kasvattaa yritysten innovaatiokykyä ja lähiajan liikevaihtoa. 3. Lisäävän valmistuksen/3D-tulostuksen käyttö yritysten TKI-toiminnassa ja tuotantolaitteistona kasvaa. 4. Materiaalien käyttö monipuolistuu ja johtaa uusien tuotteiden kehittämiseen. 5. Yhteistyö 3D-tulostuksen laitteistoja ja laitteiston osia kehittävien ja valmistavien yritysten sekä bio- ja lääkealan eri sektoreiden välillä lisääntyy ja 3D-tulostuksen osaamistaso nousee. Hanke toteutetaan yhteistyössä osallistuvien organisaatioiden kesken viiden toimenpidekokonaisuuden kautta: 1. Lääkeannosteluvalmisteiden kehittäminen 2. Hammaslääketieteen irtoproteesien valmistus 3D-tulostuksella sekä lujituksen ja valmistuksen optimointi ja suunnittelu 3. In vitro-diagnostiikan testikasettien ja testikasettien valmistuksen kehittäminen 3D-tulostuksella 4. Regulaatiotilanteen ennakointiselvitys bio- ja lääketeollisuuden 3D-tulostukseen liittyen 5. Palaute- ja suunnittelutilaisuudet yritysten kanssa.Hankkeessa monipuolisesti toteutetut 3D-tulostustestaukset eri laitteilla ja materiaaleilla tuottavat tietoa, jota kohdeyritykset hyödyntävät tuotekehityksessä ja suunnittelussa. Näitä ovat esim. käytännön tieto erilaisten bio- ja lääkesovelluksissa tarvittavien materiaalien 3D-tulostettavuudesta ja valmistusprosesseista. Yhteistyössä yritysten kanssa tehty kehitystyö tukee regulaation ja laadunvarmistuksen tulevaisuuden muutosten arvioinnissa ja ohjaa kehitystyötä oikeaan suuntaan. Materiaalien monipuolinen testaus ja käytännön kokemukset johtavat 3D-tulostuslaitteiston ja 3D-tulostusprosessien suunnittelun ja automaation kehittymiseen. 3D-tulostuksen kehittäminen monialaisesti mahdollistaa yhteistyön lisääntymisen sekä bio- ja lääkealan eri sektoreiden, että 3D laitteistoja valmistavien yritysten välillä. Tulokset vaikuttavat yritysten 3D-tulostukseen liittyvään TKI-toiminnan kasvuun ja pitemmällä aikavälillä terveydenhoidon uusien tuotteiden ja palvelujen kehittämiseen, liikevaihdon kasvuun ja työpaikkojen lisääntymiseen.Hanke edistää monin tavoin rakennerahasto-ohjelman horisontaalisia tavoitteita. Automaation ja digitalisaation hyödyntäminen sekä suunnittelun tehostaminen valmistuksen kehittämisessä vaikuttavat positiivisesti sekä ekologiseen että taloudelliseen kestävyyteen vähentäen luonnonvarojen käyttöä, materiaalien tuhlausta ja luonnolle haitallisten kemikaalien käyttöä. Hanke lisää siten ympäristöosaamista ja vaikuttaa Ilmastonmuutoksen aiheuttamien riskien vähentämiseen. Bio- ja lääketeollisuus on yksi maakunnan maakuntastrategian ja elpymissuunnitelmien kärkialoista ja hanke tukee suoraan paikallisen elinkeinorakenteen kehittämistä ja kilpailukykyä, ja edistää siten yhteiskunnan hyvinvointia. Hanke ottaa toiminnassaan huomioon myös tasa-arvon ja kulttuuriselta taustaltaan erilaiset yrittäjät, jotta hankkeesta hyötyy mahdollisimman monipuolinen ryhmä yrittäjiä. (Finnish)
0 references
Pharmaceutical and biotechnology have been identified as one of the three smart specialisation priorities in Southwest Finland. Its aim is to create the conditions for new innovations and their commercialisation through seamless cooperation between research institutes and companies in the field. The needs identified in the preparation of the Bio- and Pharmaceutical Industry (AMBioPharma) are the key to increasing the potential of these sectors. The project is based on the near-term development needs of the companies in the field and offers opportunities for new innovations and business activities by developing more manufacturing, i.e. 3D printing. The importance of 3D printing is rapidly increasing in the development of bio- and medical applications. Companies operating in the sector need to develop knowledge, materials and equipment. In summary, the conscious needs of enterprises in the V-S region relate to the efficiency and facilitation of production and the development of new products. Main objectives:1. The project will improve and accelerate companies’ product development through 3D printing of new pharmaceuticals, dentures, medical instruments and in vitro diagnostic test systems. 2. The importance of increasing manufacturing/3D-printing as part of the development of new products will increase in the bio- and pharmaceutical industry in Southwest Finland and increase companies’ innovation capacity and near-term turnover. 3. The use of increasing production/3D printing in companies’ RDI operations and production equipment is increasing. 4. The use of materials is diversified and leads to the development of new products. 5. Cooperation between companies that develop and manufacture 3D printing equipment and components, as well as different sectors of the bio- and pharmaceutical sector, will increase and the level of competence in 3D printing will increase. The project will be implemented in cooperation between the participating organisations through five sets of measures: 1. Development of medicinal products 2. Manufacture of dental loose prostheses with 3D printing and optimisation and design of reinforcement and manufacturing 3. Development of in vitro diagnostic test cassettes and test cassettes with 3D printing 4. Forecasting of the regulatory situation in relation to 3D printing in the bio- and pharmaceutical industries 5. Feedback and design events with companies. The versatile 3D printing testing carried out in the project with different devices and materials produces information that target companies use in product development and design. These include, for example, practical knowledge of 3D printability and manufacturing processes of various materials used in bio- and pharmaceutical applications. The development work carried out in cooperation with companies supports the assessment of future changes in regulation and quality assurance and directs the development work in the right direction. Versatile material testing and practical experience lead to the development of 3D printing equipment and 3D printing processes design and automation. The development of 3D printing in a multidisciplinary manner enables increased cooperation between the different sectors of the bio- and pharmaceutical sector and between companies manufacturing 3D equipment. The results contribute to the growth of RDI activities related to 3D printing and, in the longer term, to the development of new healthcare products and services, the growth of turnover and job creation.The project contributes in many ways to the horizontal objectives of the Structural Funds programme. The use of automation and digitalisation, as well as improved planning in the development of manufacturing, have a positive impact on both ecological and economic sustainability, reducing the use of natural resources, waste of materials and the use of chemicals that are harmful to nature. The project thus increases environmental know-how and contributes to reducing the risks posed by climate change. The bio- and pharmaceutical industry is one of the top priorities of the provincial regional strategy and recovery plans, and the project directly supports the development of the local economic fabric and competitiveness, thereby contributing to the well-being of society. The project also takes into account equality and entrepreneurs from different cultural backgrounds in order to benefit from the project as diverse as possible. (English)
23 November 2021
0 references